Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Lenalidomide (LEN) is increasingly being used for the treatment of multiple myeloma (MM). Adverse cutaneous reactions to LEN are common and present almost exclusively within one month of initiating therapy. We report a case of delayed-onset LEN-associated eruption presenting over three years after starting treatment. Histopathologic findings are also described, which are infrequently reported for LEN-associated eruptions. Our case serves as a reminder that proper recognition and management of LEN-associated eruption is important in the treatment of MM. Dermatologists should be aware of the potential for delayed presentations of adverse cutaneous reactions to LEN, even years after initiation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5070/D3271256713 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of Composite Measurable Residual Disease Assessment with PET-CT and flow cytometry in Multiple Myeloma patients undergoing Autologous Transplant.
Blood Cell Ther
August 2025
Department of Clinical Hematology and Medical Oncology, Postgraduate Institute Of Medical Education And Research (PGIMER), Chandigarh, India.
Background: Bone marrow (BM) Measurable Residual Disease (MRD) assessments underestimate disease burden in multiple myeloma, as focal lesions can exist outside the marrow. Functional imaging, like positron emission tomography-computed tomography (PET-CT), offers valuable insights into residual disease beyond the marrow. Combining marrow flow cytometry (FCM) with PET-CT for a composite MRD (cMRD) assessment before and after autologous stem cell transplant (ASCT) is expected to provide prognostic information, particularly in settings where patients receive extended duration of anti-myeloma therapy prior to ASCT.
View Article and Find Full Text PDFDermatological safety of humanized bispecific antibody Talquetamab: skin and nail adverse events related to a novel immunotherapy for multiple myeloma.
Ital J Dermatol Venerol
August 2025
Section of Dermatology Pistoia-Prato, USL Toscana Centro-Prato Hospital, Prato, Italy.
European Myeloma Network Consensus Statement on Functional High-Risk Multiple Myeloma.
Am J Hematol
September 2025
Australian Centre for Blood Diseases Monash University, Melbourne, Australia.
Multiple myeloma (MM) is an incurable blood cancer characterized by clonal bone marrow plasmacytosis, hypercalcemia, renal failure, anemia, and osteolytic bone disease. Approximately 20% of NDMM patients, not predicted to have high-risk disease at diagnosis, progress early, despite optimal induction +/- ASCT and lenalidomide maintenance, and are subsequently categorized as functional high-risk (FHR) disease. Standardized risk-stratification models incorporate biomarkers of tumor burden, existence of high-risk cytogenetics, with the presence/absence of plasma cell leukemia/extramedullary disease to attribute high-risk at diagnosis; however, depth/duration of response to novel agent-based induction (NA-IND) as dynamic markers of disease risk have not been defined.
View Article and Find Full Text PDFA Rare Case of Plasmablastic Myeloma After Renal Transplant.
Exp Clin Transplant
August 2025
>From the University Clinic for Nephrology, Faculty of Medicine, Saints Cyril and Methodius University in Skopje, Skopje, North Macedonia.
Posttransplant lymphoproliferative disorders are a serious complication after solid-organ transplant, with a reported incidence from 2% to 20%. Plasma cell neoplasms in solid-organ transplants represent a rare but increasingly serious complication after solid-organ transplant. We report a case of plasmablastic myeloma, a very rare variant of multiple myeloma with aggressive course and poor prognosis.
View Article and Find Full Text PDFMultiple myeloma complicated with spinal infiltration: a case report.
Neurol Sci
September 2025
Department of Neurosurgery, The 940, Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, No.333 Nanbinhe Road, Qilihe District, Lanzhou City, Gansu Province, China.